To address the need to intervene to prevent the spread of COVID-19 in long-term care homes,
we propose a randomized clinical trial of chemoprophylaxis in long-term care homes
experiencing COVID-19 outbreaks. LTCH units experiencing an outbreak of COVID-19 will be
randomized to chemoprophylaxis with favipiravir or placebo in a 1:1 ratio.
Chemoprophylaxis in this setting refers to the use of favipiravir for pre-exposure
prophylaxis, post-exposure prophylaxis, pre-emptive therapy, or treatment for established
COVID-19. This design mimics the approach to influenza outbreaks, which has proven efficacy
for outbreak control. The primary outcome will be control of the outbreak, defined as no new
microbiologically confirmed case of COVID-19 for 24 consecutive days up to day 40.
Phase:
Phase 2
Details
Lead Sponsor:
Appili Therapeutics Inc.
Collaborators:
Applied Health Research Centre MOUNT SINAI HOSPITAL Sunnybrook Health Sciences Centre University Health Network, Toronto University of Toronto